Adial Pharmaceuticals(ADIL.US)

Last Updated 19:00:00 ET
longbridge loading

MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch

rttnews·
US
ADIL
+10.19%
US
BDTX
+20.00%
US
EDSA
-8.37%
rttnews·
US
ADIL
+10.19%
US
BDTX
+20.00%
US
EDSA
-8.37%

Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained

Tip Ranks·
US
ADIL
+10.19%
US
FBT
+1.61%
US
LABU
+11.37%
Tip Ranks·
US
ADIL
+10.19%
US
FBT
+1.61%
US
LABU
+11.37%

ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov | ADIA Stock News

StockTitan·
US
ADIL
+10.19%
US
XLV
-0.31%
US
ARKG
+4.23%
StockTitan·
US
ADIL
+10.19%
US
XLV
-0.31%
US
ARKG
+4.23%

Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk

Tip Ranks·
US
ADIL
+10.19%
US
IBB
+1.98%
US
ARKG
+4.23%
Tip Ranks·
US
ADIL
+10.19%
US
IBB
+1.98%
US
ARKG
+4.23%

00:00 ETAlebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

prnewswire·
US
ADIL
+10.19%
US
BMRN
+1.06%
US
VRTX
-1.15%
prnewswire·
US
ADIL
+10.19%
US
BMRN
+1.06%
US
VRTX
-1.15%

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | ADIL Stock News

StockTitan·
US
ADIL
+10.19%
US
XBI
+3.76%
US
VHT
+0.07%
StockTitan·
US
ADIL
+10.19%
US
XBI
+3.76%
US
VHT
+0.07%

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | ADIL Stock News

StockTitan·
US
ADIL
+10.19%
US
IBB
+1.98%
US
PBE
+1.36%
StockTitan·
US
ADIL
+10.19%
US
IBB
+1.98%
US
PBE
+1.36%
© 2026 Longbridge｜Disclaimer